EVALUATION OF THE CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF NEUROBLASTOMA
DOI:
https://doi.org/10.56238/arev7n11-396Keywords:
Neoplasm, Children, Clinical Characteristics, DiagnosisAbstract
Neuroblastoma is a malignant neoplasm of embryonic origin that affects children and is notable for its considerable clinical and biological heterogeneity. This study aims to analyze the clinical, epidemiological, and therapeutic characteristics of neuroblastoma, as well as understand how these variables influence the diagnostic process of patients. The disease is most common in children under five years of age and is usually detected in advanced stages, reinforcing the importance of early diagnosis and multidisciplinary follow-up.
Downloads
References
ANDERSON, John; MAJZNER, Robbie G.; SONDEL, Paul M. Immunotherapy of neuroblastoma: facts and hopes. Clinical Cancer Research, v. 28, n. 15, p. 3196-3206, 2022.
BAGATELL, R.; PARK, J. R.; ACHARYA, S. et al. Neuroblastoma, Version 2.2024. JNCCN: Journal of the National Comprehensive Cancer Network, v. 22, n. 6, p. 413–433, 2024.
BERGAGGIO, E.; et al. ALK inhibitors increase ALK expression and sensitize neuroblastoma to ALK-directed CAR-T therapy. Cancer Cell (article/communication), 2023.
BERTHOLD, F.; ROSSWOG, C.; CHRISTIANSEN, H.; FRÜHWALD, M.; HEMSTEDT, N.; KLINGEBIEL, T.; FRÖHLICH, B.; SCHILLING, F. H.; SCHMID, I.; SIMON, T.; HERO, B.; FISCHER, M.; ERNST, A. Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification. Pediatric Blood & Cancer, v. 68, n. 8, e29038, 2021.
DEL BUFALO, Francesca et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. New England Journal of medicine, v. 388, n. 14, p. 1284-1295, 2023.
FANG, X.; et al. Clinical features of children with retinoblastoma and neuroblastoma in China. International Journal of Pediatrics, 2020.
IRWIN, M. S.; NARANJO, A.; ZHANG, F. F. et al. Revised Neuroblastoma Risk Classification System: A Report From the Children’s Oncology Group. Journal of Clinical Oncology, v. 39, n. 29, p. 3229–3241, 2021.
LUCENA, Januária Nunes et al. Aspectos clínicos, epidemiológicos e sobrevida de crianças com neuroblastoma: 21 anos de experiência do instituto de oncologia pediátrica, São Paulo. Revista Paulista de Pediatria, v. 36, n. 03, p. 254-260, 2018.
NEWMAN, Erika A. et al. Update on neuroblastoma. Journal of pediatric surgery, v. 54, n. 3, p. 383-389, 2019.
NONG, J.; et al. Temporal trends in cross-country inequalities of neuroblastoma burden in children under 14 years of age from 1990 to 2021. 2024.
ONYIJE, F. M.; DOLATKHAH, R.; OLSSON, A. et al. Risk factors of neuroblastoma: a systematic review and meta-analysis. Frontiers in Public Health, 2025.
PONZONI, Mirco et al. Recent advances in the developmental origin of neuroblastoma: an overview. Journal of Experimental & Clinical Cancer Research, v. 41, n. 1, p. 92, 2022.
QIU, B.; MATTHAY, K. K. Advancing therapy for neuroblastoma. Nature Reviews
Wahba, A.; et al. Neuroblastoma in the era of precision medicine: a clinical review. Cancers, 2023.
WARLET, Fernanda et al. Neuroblastoma infantil: características clínicas, tratamento e prognóstico. Acta médica, v. 39, n. 2, p. 260, 2018.
WULF, A. M.; MORENO, M. M.; PAKA, C.; RAMPASEKOVA, A.; LIU, K. J. Defining pathological activities of ALK in neuroblastoma, a neural-crest derived cancer. International Journal of Molecular Sciences, v. 22, n. 21, p. 11718, 2021.
ZHENG, D. J.; et al. Socioeconomic disparities in survival after high-risk neuroblastoma treatment with modern therapy. Pediatric Blood & Cancer, 2021.
ZEINELDIN, Maged; PATEL, Anand G.; DYER, Michael A. Neuroblastoma: When differentiation goes awry. Neuron, v. 110, n. 18, p. 2916-2928, 2022.
